

Q1 could immunodeficiency-type retrovirus comprising administering an effective amount of a peptide selected from the group consisting of peptides comprising the amino acid sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), or a derivative thereof, to an individual free of infection with an immunodeficiency-type retrovirus in an amount sufficient to increase production of at least one Th1 cytokine or decrease production of at least one Th2 cytokine.

Q2 24. (Amended) The method according to claim 7 in which the Th1 cytokine is selected from the group consisting of interleukin 2 and interferon- γ .

25. (Amended) The method according to claim 7 in which the Th2 cytokine is selected from the group consisting of interleukin-4, interleukin 5, interleukin 6, interleukin 10 and immunoglobulin G.

IN THE ABSTRACT

Please amend the Abstract on page 32 of the application as filed to read as follows:

Q3 The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof. The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods.

REMARKS

Upon entry of this Reply, claims 7, 24, and 25 will be pending and under active consideration. Claims 1-6 and 8-23 have been canceled without prejudice. Specifically, claims 1-6 and 8-23 have been canceled due to their withdrawal from consideration in view of the restriction requirement of October 2, 2001. Applicants reserve the right to prosecute the subject matter of these canceled claims in one or more related